Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
NCT ID: NCT05009082
Last Updated: 2025-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
970 participants
INTERVENTIONAL
2022-09-13
2031-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer
NCT05183984
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
NCT06141265
Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer
NCT02354131
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
NCT03806049
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT03326193
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All eligible patients will receive the first cycle of chemotherapy (carboplatin area under curve \[AUC\] 5 and paclitaxel 175 mg/m²) as part of Study Run-In-Period (cycle 1). In parallel, central laboratory will determine the breast cancer (BRCA) status in tumor tissue (tBRCA). All patients with a valid central tBRCA test result will be randomized within 3 days prior to day 1 of cycle 2 in a 1:1 ratio in the following treatment arms:
Arm 1: Patients will receive further 5 cycles of carboplatin and paclitaxel q21d followed by niraparib once daily for up to a total of 3 years
Arm 2: Patients will receive further 5 cycles of carboplatin and paclitaxel plus bevacizumab q21d followed by bevacizumab q21d (for up to 1 year) and niraparib once daily for up to a total of 3 years.
The study aims to investigate, if the treatment strategy of carboplatin / paclitaxel / bevacizumab / niraparib is superior to the treatment of carboplatin / paclitaxel / niraparib-Inhibitor in an all-comer population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Chemotherapy followed by maintenance with niraparib
Carboplatin
Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles
Paclitaxel
175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles
Niraparib
200 or 300 mg capsules once daily for up to a total of 3 years starting from Cycle 7 Day 1
Arm 2
Chemotherapy in combination with bevacizumab followed by maintenance with bevacizumab and niraparib
Carboplatin
Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles
Paclitaxel
175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles
Bevacizumab
7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year starting from Cycle 7 Day 1
Niraparib
200 or 300 mg capsules once daily for up to a total of 3 years starting from Cycle 7 Day 1
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carboplatin
Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles
Paclitaxel
175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles
Bevacizumab
7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year starting from Cycle 7 Day 1
Niraparib
200 or 300 mg capsules once daily for up to a total of 3 years starting from Cycle 7 Day 1
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Female patients ≥ 18 years with histologically confirmed primary advanced invasive high grade non-mucinous, non-clear cell epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer FIGO III/IV (except FIGO stage IIIA2 without nodal involvement) according to recent FIGO classification (= FIGO stage IIIB - IV according to FIGO 2009 classification).
3. All patients must have had either upfront primary debulking surgery OR plan to undergo chemotherapy with interval debulking surgery.
4. Patients must have available tumor samples to be sent to central laboratory as formalin-fixed, paraffin-embedded (FFPE) sample for determination of BRCA status prior to randomization for stratification.
5. Patients must be able to commence systemic therapy within 8 weeks of cytoreductive surgery.
6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
7. Estimated life expectancy \> 3 months.
8. Adequate bone marrow function (within 28 days prior to day 1, cycle 1 and within 3 days prior to day 1, cycle 2)
* Absolute Neutrophil Count (ANC) ≥ 1.5 x 10\^9/L
* Platelets (PLT) ≥ 100 x 10\^9/L
* Hemoglobin (Hb) ≥ 9 g/dL (can be post-transfusion)
9. Adequate coagulation parameters (within 28 days prior to day 1, cycle 1 and within 7 days prior to day 1, cycle 2)
* Patients not receiving anticoagulant medication who have an International Normalized Ratio (INR) ≤ 1.5 and an Activated ProThrombin Time (aPTT) ≤ 1.5 x institutional upper limit of normal (ULN).
* The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to institution medical standard) and the patient has been on a stable dose of anticoagulants for at least one week at the time of randomization.
10. Adequate liver and kidney function (within 28 days prior to day 1, cycle 1 and within 3 days prior to day 1, cycle 2)
* Total bilirubin ≤ 1.5 x ULN (≤ 2.0 x ULN in patients with known Gilbert's syndrome) OR direct bilirubin ≤ 1.0 x ULN.
* Aspartate aminotransferase / Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT) and Alanine aminotransferase / Serum Glutamic Pyruvate Transaminase (ALAT/SGPT) ≤ 2.5 x ULN, unless liver metastases are present, in case of liver metastases values must be ≤ 5 x ULN.
* Urine dipstick for proteinuria \< 2+. If urine dipstick is ≥ 2+, 24 hour urine must demonstrate ≤ 1 g of protein in 24 hours.
* Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 30 mL/min (see Appendix 2).
11. Patients must have normal blood pressure (BP) or adequately treated and controlled BP, with a systolic BP of ≤ 140 mmHg and diastolic BP of ≤ 90 mmHg for eligibility. Patients must have a BP of ≤ 140/90 mmHg taken in the clinic setting by a medical professional within 4 weeks prior to day 1, cycle 1 and within 7 days prior to day 1, cycle 2.
12. Negative urine or serum pregnancy test within 7 days prior to day 1, cycle 1 in women of childbearing potential (WOCBP), confirmed prior to treatment on day 1.
13. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method with a failure rate of \< 1% per year during the treatment period and for at least 6 months after administration of the last dose of medication.
A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries, fallopian tubes, and/or uterus).
Examples of contraceptive methods with a failure rate of \< 1% per year include but are not limited to bilateral tubal ligation and/or occlusion, male sterilization, and intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
14. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other clinical trial procedures, that include the completion of patient-reported outcomes questionnaires.
Exclusion Criteria
2. Ovarian tumors of low malignant potential (e.g. borderline tumors) and low grade tumors.
3. Planned intraperitoneal cytotoxic chemotherapy.
4. Malignancies other than ovarian cancer within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS rate \> 90%) and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, ductal carcinoma in situ of the breast, or stage I p53 wild type endometrial cancer).
5. Prior systemic treatment for ovarian cancer.
6. Prior treatment with Poly adenosine diphosphate ribose polymerase (PARP) inhibitor.
7. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted).
8. Prior randomization in this trial.
9. Major surgery within 1 week of starting study treatment or patient who has not completely recovered from the effects of any major surgery. Core biopsy or other minor surgical procedure within 7 days prior to day 1, cycle 1 is permitted.
10. History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of the brain is mandatory (within 4 weeks prior to day 1, cycle 1) in case of suspected brain metastases. Spinal MRI is mandatory (within 4 weeks prior to day 1, cycle 1) in case of suspected spinal cord compression.
11. Significant traumatic injury during 4 weeks preceding the potential first dose of bevacizumab.
12. Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or Sub-Arachnoids Hemorrhage (SAH) within 6 months prior to day 1, cycle 1.
13. History or evidence of thrombotic or hemorrhagic disorders within 3 months prior to day 1, cycle 1.
14. History or evidence upon neurological examination of central nervous system (CNS) disease, unless adequately treated with standard medical therapy e.g. uncontrolled seizures.
15. Pregnant or lactating women.
16. Treatment with any other investigational agent, or participation in another clinical trial testing a drug within 4 weeks or 5 times the half-life of the drug, whichever is longer, prior to day 1, cycle 1 or concomitantly within this trial.
17. Known hypersensitivity to bevacizumab and its excipients, Chinese hamster ovary cell products or other recombinant human or humanized antibodies. Known hypersensitivity to niraparib, paclitaxel and carboplatin and its components or excipients.
18. Non-healing wound, active ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no severe evidence of facial dehiscence or infection are eligible; regular wound examination will be performed.
19. Clinically significant cardiovascular disease, including
* Myocardial infarction or unstable angina within 6 months of day 1, cycle 1
* New York Heart Association (NYHA) Grade 2 Congestive Heart Failure (CHF),
* Poorly controlled cardiac arrhythmia despite medication (patients with rate-controlled atrial fibrillation are eligible)
* Grade ≥ 3 peripheral vascular disease (i.e. symptomatic and interfering with activity of daily living (ADL) requiring repair or revision)
* Significant vascular disease including aortic aneurysm requiring surgical repair
20. Pre-existing sensory or motor neuropathy ≥ Grade 2.
21. (Intentionally left blank)
22. Patients with a history of or current Nephrotic syndrome.
23. Persistent cancer-related bowel obstruction (including subocclusive disease). Patients with a known history of ileus, who have been successfully treated and who are free of symptoms, may be eligible after consultation of sponsor.
24. History of abdominal fistula or tracheoesophageal fistula or gastrointestinal perforation or active gastrointestinal bleeding or anastomotic insufficiency within 6 months of day 1, cycle 1.
25. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of niraparib.
26. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.
27. Any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
28. Previous allogeneic bone marrow transplant or previous solid organ transplantation.
29. Current or recent (within 10 days prior to day 1, cycle 1) chronic use of aspirin \> 325 mg/day. Patients treated with other inhibitors of platelet aggregation such as clopidogrel, prasugrel, ticlopidine, tirofibane or dipyridamole should not be included into the trial.
30. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. This includes also any psychiatric disorder that prohibits obtaining informed consent.
31. Patient has known active hepatitis B or hepatitis C.
32. Patient has a history of Posterior Reversible Encephalopathy Syndrome (PRES).
33. Patients with chronic inflammatory bowel disease and active treatment for disease control.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
AGO Study Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philipp Harter, MD, PhD
Role: STUDY_CHAIR
KEM Essen | Evang. Kliniken Essen-Mitte gGmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinikum St. Marien Amberg
Amberg, , Germany
Klinikum Augsburg
Augsburg, , Germany
Hochtaunus-Kliniken
Bad Homburg, , Germany
Helios Klinikum Berlin-Buch
Berlin, , Germany
Onkologische Schwerpunktpraxis Bielefeld
Bielefeld, , Germany
Städt. Klinikum Brandenburg
Brandenburg, , Germany
Klinikum Bremen Mitte
Bremen, , Germany
Klinikum Chemnitz
Chemnitz, , Germany
St. Elisabeth-Krankenhaus Köln-Hohenlind
Cologne, , Germany
Klinikum Dortmund
Dortmund, , Germany
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, , Germany
Florence-Nightingale-Krankenhaus Düsseldorf
Düsseldorf, , Germany
Universitätsfrauenklinik Düsseldorf
Düsseldorf, , Germany
KEM Essen | Evang. Kliniken Essen-Mitte gGmbH
Essen, , Germany
Universitätsklinikum Essen
Essen, , Germany
Klinikum Esslingen GmbH
Esslingen am Neckar, , Germany
Universitätsklinikum Frankfurt
Frankfurt, , Germany
Klinikum Frankfurt Höchst
Frankfurt am Main, , Germany
Universitätsklinikum Gießen
Giessen, , Germany
Klinikum Gütersloh
Gütersloh, , Germany
Universitätsklinikum Halle
Halle, , Germany
Albertinen Krankenhaus
Hamburg, , Germany
Mammazentrum HH am Krankenhaus Jerusalem
Hamburg, , Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, , Germany
Gynäkologisch-Onkologische Praxis am Pelikanplatz
Hanover, , Germany
Universitätsklnikum Heidelberg
Heidelberg, , Germany
Klinikum am Gesundbrunnen / SLK-Kliniken Heilbronn GmbH
Heilbronn, , Germany
Gyn.-onkolog. Gemeinschaftspraxis Hildesheim
Hildesheim, , Germany
Universtitätsklinikum Jena
Jena, , Germany
Städtisches Klinikum Karlsruhe
Karlsruhe, , Germany
ViDia Christliche Kliniken Karlsruhe
Karlsruhe, , Germany
Klinikum Kassel
Kassel, , Germany
Klinikverbund Kempten-Oberallgäu gGmbH
Kempten, , Germany
Klinikum Konstanz
Konstanz, , Germany
Zentrum für ambulante gynäkologische Onkologie am HELIOS Klinikum Krefeld
Krefeld, , Germany
Universitätsklinikum Leipzig
Leipzig, , Germany
St. Vincenz Krankenhaus
Limburg, , Germany
Klinikum Ludwigsburg
Ludwigsburg, , Germany
UKSH Campus Lübeck
Lübeck, , Germany
Universitätsmedizin Mainz
Mainz, , Germany
Universitätsklinikum Mannheim GmbH
Mannheim, , Germany
UKGM Gießen/Marburg Standort Marburg
Marburg, , Germany
Mühlenkreiskliniken, Johannes Wesling Klinikum Minden
Minden, , Germany
LMU Klinikum München-Großhadern
München, , Germany
Rotkreuzklinikum München
München, , Germany
Universitätsklinikum Münster
Münster, , Germany
Klinikum Neumarkt
Neumarkt, , Germany
MVZ Nordhausen
Nordhausen, , Germany
Ortenau Klinikum Offenburg-Kehl
Offenburg, , Germany
St. Vincenz Krankenhaus GmbH
Paderborn, , Germany
Studienzentrum Onkologie Ravensburg
Ravensburg, , Germany
Krankenhaus Barmherzige Brüder
Regensburg, , Germany
Klinikum am Steinenberg
Reutlingen, , Germany
RoMed Klinikum Rosenheim
Rosenheim, , Germany
Klinikum Südstadt Rostock
Rostock, , Germany
Thüringen-Kliniken "Georgius Agricola"
Saalfeld, , Germany
Leopoldina Krankenhaus Schweinfurt
Schweinfurt, , Germany
g.SUND
Stralsund, , Germany
Klinikum Stuttgart
Stuttgart, , Germany
Klinikum Traunstein
Traunstein, , Germany
Klinikum Mutterhaus
Trier, , Germany
Universitätsklinikum Tübingen
Tübingen, , Germany
Universitätsklinik Ulm
Ulm, , Germany
St. Josefs-Hospital
Wiesbaden, , Germany
Klinikum Worms
Worms, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Heitz F, Marth C, Henry S, Reuss A, Cibula D, Gaba Garcia L, Colombo N, Schmalfeld B, de Gregorio N, Wimberger P, Hasenburg A, Sehouli J, Gropp-Meier M, Schouten PC, Hahnen E, Hauke J, Polleis S, Harter P. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial. Int J Gynecol Cancer. 2023 Dec 4;33(12):1966-1969. doi: 10.1136/ijgc-2023-004944.
Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-516066-11-00
Identifier Type: CTIS
Identifier Source: secondary_id
2021-001271-16
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
ENGOT-ov57
Identifier Type: OTHER
Identifier Source: secondary_id
AGO-OVAR 28
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.